# C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

> **NCT01005888** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 26 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **BIOLOGICAL:** C1 esterase inhibitor [human] (C1INH-nf)
- **DRUG:** Placebo (saline)

## Key facts

- **NCT ID:** NCT01005888
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-14
- **Primary completion:** 2007-08-22
- **Final completion:** 2007-08-22
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005888, "C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01005888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*